The initial funding round brings backing from major financial institutions to accelerate compliance screening technology.
"Sanctions screening is both an international security imperative and one of the major sources of friction in the global payment system – at a time when consumers and businesses are increasingly demanding real-time settlement . GSS is uniquely position to deliver improved regulatory compliance and an enhanced customer experience. We’re delighted to have closed this funding round and to be working with such incredible partners to take GSS to market."
The financial crime platform has secured £3.1m in a pre-series a funding round.
"An estimated 2.7% of global GDP is lost every year to money laundering and associated crimes, enriching criminals and organised crime groups at the expense of people, businesses and our planet, so the importance of ramping up our collective ability to detect and disrupt these threats cannot be underestimated. Through its technology, insight and intelligence, Themis aims to help individuals, businesses, not-for-profit organisations and governments to address their financial crime risks. We couldn’t be more excited about the direction we’re headed in the new year"
Snowflake Ventures backed the Leeds-based decision intelligence company following its success in the 2022 Snowflake Startup Challenge.
"As we reviewed hundreds of entries from companies building products and applications on Snowflake, HyperFinity stood out in how the platform aligns with our Retail Data Cloud partner strategy. Over the coming months we’ll work closely with HyperFinity as they build out their decision intelligence platform and continue with their already impressive client traction."
— Stefan Williams, VP of Corporate Development and Snowflake Ventures
The funding round was led by Eka Ventures and will support international studies and product development.
"Existing data suggests that current approaches fall short at accurately detecting and localizing the deadliest cancers that desperately need to benefit from a blood test. At OXcan, we are using state-of-art and unbiased high-throughput proteomics approaches to examine hundreds and thousands of proteins in blood samples from largest studies of their kind for the first time. Combined with proprietary and tailored machine learning approaches, the results are products that fully integrate with existing care pathways and can detect and localize the deadliest cancers with unprecedented sensitivity and specificity."
The cyber-security business secured the investment to support its sales strategy and reach new markets.
"This is a great addition to our funding round and we are very grateful for the help and guidance provided by Henley Business Angels. We are looking forward to updating the members with the progress made."
